Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma

BACKGROUND: The optimal treatment for metastatic renal cell carcinoma (mRCC) patients who have progressed after both immune checkpoint inhibitor (ICI) and VEGFR tyrosine kinase inhibitor (TKI) remains uncertain. Lenvatinib and everolimus (LE) are frequently used in combination as salvage therapy bec...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwok, Christopher, Khorasanchi, Adam, Psutka, Sarah P., Hinkley, Megan, Dason, Shawn, Sundi, Debasish, Yang, Yuanquan, Yang, Yajing, Verschraegen, Claire, Gross, Evan E., Orcutt, Delaney, Yin, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412983/
https://www.ncbi.nlm.nih.gov/pubmed/37576889
http://dx.doi.org/10.3389/fonc.2023.1231831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412983/
https://www.ncbi.nlm.nih.gov/pubmed/37576889
http://dx.doi.org/10.3389/fonc.2023.1231831

Ejemplares similares